Silosai is an innovative nano-drug developer. The company focuses on the development and application of new nano-drugs, especially exosome-related innovative drugs. Clinical application translation. In addition, based on the professional and complete TAXY™ exosome research platform, the company also provides scientific research CRO services and clinical CDMO services in related fields to help the rapid development of the exosome industry. Recently, Siluosai announced the completion of more than ten million US dollars of Pre-A round of financing. This financing will be used for the construction of the company’s programmatic drug delivery platform TAXY ™ and the promotion of CDMO business. Novo Ventures and another well-known medical investment fund jointly led the investment.
This article is reproduced from: https://www.itjuzi.com/investevent/13334256
This site is for inclusion only, and the copyright belongs to the original author.